Gyroscope Therapeutics has raised £50.4m ($60.3m) in a series B fundraising which will fuel the ongoing development of its lead gene therapies and surgical delivery systems for retinal diseases.
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?